Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Darwin, MSI2, and relapse in T-ALL

João T. Barata

Blood (2024) 143 (4): 294–296.

https://doi.org/10.1182/blood.2023022490

Published: 2024

Journal Articles

Dependence of IL-7R-Mediated Signaling on Sphingosine Kinase Activity in Acute Lymphoblastic Leukemia, but Not Healthy Lymphoid Cells, Is an Exploitable Therapeutic Vulnerability

Marta B Fernandes, Alice Melão, Tatiana Araújo, Ana Cachucho, David R Adams, Jeongah Oh, Afonso R M Almeida, Federico Torta, Vasco Barreto, Susan Pyne, Timothy Hla, Nigel J Pyne, Joao T Barata

Blood (2023) 142 (Supplement 1): 38.

https://doi.org/10.1182/blood-2023-186707

Published: 2023

Journal Articles

INPP5K controls the dynamic structure and signaling of wild-type and mutated, leukemia-associated IL-7 receptors

Bastien Moës, Hua Li, Patricia Molina-Ortiz, Coraline Radermecker, Adeline Rosu, Charles-Andrew Vande Catsyne, Sufyan Ali Sayyed, João Fontela, Mafalda Duque, Alice Mostafa, Abdelhalim Azzi, João T. Barata, Ramon Merino, Chenqi Xu, Christophe J. Desmet, Stéphane Schurmans

Blood (2023) 141 (14): 1708–1717.

https://doi.org/10.1182/blood.2022017819

Published: 2023

Includes: Supplemental data

Journal Articles

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

Ana Silva, Afonso R. M. Almeida, Ana Cachucho, João L. Neto, Sofie Demeyer, Mafalda de Matos, Thea Hogan, Yunlei Li, Jules Meijerink, Jan Cools, Ana Rita Grosso, Benedict Seddon, João T. Barata

Blood (2021) 138 (12): 1040–1052.

https://doi.org/10.1182/blood.2019000553

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma

Blood (2020) 135 (19): 1685–1695.

https://doi.org/10.1182/blood.2019003880

Published: 2020

Includes: Supplemental data

Journal Articles

The JAK Inhibitor Ruxolitinib Is Effective in Treating T Cell Acute Lymphoblastic Leukemia with Gain of Function Mutations in IL-7R Alpha

Emilee Senkevitch, PhD BS, Julie Hixon, Caroline Andrews, Joao T Barata, PhD, Wenqing Li, Scott Durum

Blood (2015) 126 (23): 1330.

https://doi.org/10.1182/blood.V126.23.1330.1330

Published: 2015

Journal Articles

Bone Marrow Stroma Protects BCR-ABL-Negative Myeloproliferative Neoplasms from Ruxolitinib- and Vorinostat-Induced Apoptosis

Bruno A Cardoso, PhD, Helio Belo, MSc, Ana Isabel Oliveira, MSc, Olga Pereira, MSc, Joao T Barata, PhD, Antonio Almeida, MD PhD

Blood (2014) 124 (21): 910.

https://doi.org/10.1182/blood.V124.21.910.910

Published: 2014

Journal Articles

PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events

Rui D. Mendes, Leonor M. Sarmento, Kirsten Canté-Barrett, Linda Zuurbier, Jessica G. C. A. M. Buijs-Gladdines, Vanda Póvoa, Willem K. Smits, Miguel Abecasis, J. Andres Yunes, Edwin Sonneveld, Martin A. Horstmann, Rob Pieters, João T. Barata, Jules P. P. Meijerink

Blood (2014) 124 (4): 567–578.

https://doi.org/10.1182/blood-2014-03-562751

Published: 2014

Includes: Supplemental data

Journal Articles

IL-7Rα: Mr Hyde’s twists and turns

João T. Barata

Blood (2013) 122 (26): 4151–4152.

https://doi.org/10.1182/blood-2013-11-536987

Published: 2013

Journal Articles

CK2 Basal Activity Regulates IL-7-Mediated JAK/STAT and PI3K/Akt Pathway Activation and Pro-Survival Effects in T-Cell Acute Lymphoblastic Leukemia Cells

Alice Melao, Ana Girio, PhD, Joao T. Barata, PhD

Blood (2012) 120 (21): 1242.

https://doi.org/10.1182/blood.V120.21.1242.1242

Published: 2012

Journal Articles

The Role of IL7R in the Induction and Maintenance of T-Cell Leukemia/Lymphoma in Vivo

Ana Silva, PhD, Joao T. Barata, PhD, Benedict Seddon, MD, PhD

Blood (2012) 120 (21): 116.

https://doi.org/10.1182/blood.V120.21.116.116

Published: 2012

Journal Articles

STAT5 Activation Is Mandatory for IL-7-Mediated Viability and Growth of T-Cell Acute Lymphoblastic Leukemia Cells

Daniel Ribeiro, Ana Silva, PhD, Bruno A. Cardoso, PhD, Joao T. Barata, PhD

Blood (2012) 120 (21): 3530.

https://doi.org/10.1182/blood.V120.21.3530.3530

Published: 2012

Journal Articles

In Vitro and in Vivo Targeting of Chronic Lymphocytic Leukemia Using CX-4945, a Clinical-Stage CK2-Specific Inhibitor.

Leila R. Martins, DVM, Paulo Lúcio, MD, PhD, Alice Melao, Bruno A. Cardoso, PhD, Ryan Stansfield, Denis Drygin, PhD, Maria Gomes Silva, MD, PhD, Joao T. Barata, PhD

Blood (2012) 120 (21): 2897.

https://doi.org/10.1182/blood.V120.21.2897.2897

Published: 2012

Journal Articles

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia

Leila R. Martins, Paulo Lúcio, Milene C. Silva, Kenna L. Anderes, Paula Gameiro, Maria G. Silva, João T. Barata

Blood (2010) 116 (15): 2724–2731.

https://doi.org/10.1182/blood-2010-04-277947

Published: 2010

Includes: Supplemental data

Journal Articles

IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells

Catarina M. Henriques, José Rino, Robert J. Nibbs, Gerry J. Graham, João T. Barata

Blood (2010) 115 (16): 3269–3277.

https://doi.org/10.1182/blood-2009-10-246876

Published: 2010

Includes: Multimedia, Supplemental data

Journal Articles

The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity

Telma Lança, Daniel V. Correia, Catarina F. Moita, Helena Raquel, Ana Neves-Costa, Cristina Ferreira, José S. Ramalho, João T. Barata, Luís F. Moita, Anita Q. Gomes, Bruno Silva-Santos

Blood (2010) 115 (12): 2407–2411.

https://doi.org/10.1182/blood-2009-08-237123

Published: 2010

Journal Articles

Targeting CK2 Overexpression as a Novel Therapeutic Tool in Chronic Lymphocytic Leukemia.

Leila R. Martins, Paulo Lúcio, MD, PhD, Paula Gameiro, MD, Maria Gomes Silva, MD, PhD, Joao T Barata, PhD

Blood (2009) 114 (22): 803.

https://doi.org/10.1182/blood.V114.22.803.803

Published: 2009

Journal Articles

IL-7 sustains CD31 expression in human naive CD4 + T cells and preferentially expands the CD31 + subset in a PI3K-dependent manner

Rita I. Azevedo, Maria Vieira D. Soares, João T. Barata, Rita Tendeiro, Ana Serra-Caetano, Rui M. M. Victorino, Ana E. Sousa

Blood (2009) 113 (13): 2999–3007.

https://doi.org/10.1182/blood-2008-07-166223

Published: 2009

Includes: Supplemental data

Journal Articles

mTOR as Therapeutic Target for T-Cell Leukemia: Synergism with Conventional Cytotoxic Drugs and Signaling Inhibitors.

Ana Batista, MSc, Joao T. Barata, PhD, Lara F. Costa, Stephen E. Sallan, MD, Nadia Carlesso, MD, PhD, Lee M. Nadler, MD, Angelo A. Cardoso, MD, PhD

Blood (2004) 104 (11): 521.

https://doi.org/10.1182/blood.V104.11.521.521

Published: 2004

Journal Articles

Crosstalk between Breast Cancer Cells and Bone Marrow Endothelium Require the Engagement of PI3K/AKT Signaling.

Joana G. Brandao, Joao T. Barata, PhD, Raquel Nunes, MD, Lee M. Nadler, MD, Angelo A. Cardoso, MD, PhD

Blood (2004) 104 (11): 1299.

https://doi.org/10.1182/blood.V104.11.1299.1299

Published: 2004

NARROW

Darwin, MSI2, and relapse in T-ALL

Dependence of IL-7R-Mediated Signaling on Sphingosine Kinase Activity in Acute Lymphoblastic Leukemia, but Not Healthy Lymphoid Cells, Is an Exploitable Therapeutic Vulnerability

INPP5K controls the dynamic structure and signaling of wild-type and mutated, leukemia-associated IL-7 receptors

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma

The JAK Inhibitor Ruxolitinib Is Effective in Treating T Cell Acute Lymphoblastic Leukemia with Gain of Function Mutations in IL-7R Alpha

Bone Marrow Stroma Protects BCR-ABL-Negative Myeloproliferative Neoplasms from Ruxolitinib- and Vorinostat-Induced Apoptosis

PTEN microdeletions in T-cell acute lymphoblastic leukemia are caused by illegitimate RAG-mediated recombination events

IL-7Rα: Mr Hyde’s twists and turns

CK2 Basal Activity Regulates IL-7-Mediated JAK/STAT and PI3K/Akt Pathway Activation and Pro-Survival Effects in T-Cell Acute Lymphoblastic Leukemia Cells

The Role of IL7R in the Induction and Maintenance of T-Cell Leukemia/Lymphoma in Vivo

STAT5 Activation Is Mandatory for IL-7-Mediated Viability and Growth of T-Cell Acute Lymphoblastic Leukemia Cells

In Vitro and in Vivo Targeting of Chronic Lymphocytic Leukemia Using CX-4945, a Clinical-Stage CK2-Specific Inhibitor.

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia

IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Rα in T cells

The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity

Targeting CK2 Overexpression as a Novel Therapeutic Tool in Chronic Lymphocytic Leukemia.

IL-7 sustains CD31 expression in human naive CD4 + T cells and preferentially expands the CD31 + subset in a PI3K-dependent manner

mTOR as Therapeutic Target for T-Cell Leukemia: Synergism with Conventional Cytotoxic Drugs and Signaling Inhibitors.

Crosstalk between Breast Cancer Cells and Bone Marrow Endothelium Require the Engagement of PI3K/AKT Signaling.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only